high serum levels of IFN whereas AIPP (2-amino-5-iodo-6-phenyl-4-pyrimidinone) does not. Yet, both agents are equally active in enhancing NK cell activity (Lotzova et al., 1983) . In a previous communition (Marquet et al., 1983) we have shown that subcutaneous growth of liposarcoma LS175 in BN rats is inhibited by IFN. This nonimmunogenic liposarcoma is of spontaneous origin and has been found to be NK resistant. In order to investigate whether the induction of IFN plays a part in the antitumour effects of ABPP and AIPP we compared the two agents in the subcutaneous and in the artificial lung metastasis model, using tumour LS175. Ten to 12-week old male BN rats were used in all experiments. The NK cell activity in peripheral blood lymphocytes (PBL) after the intraperitoneal administration of 250mg kg-1 of ABPP or AIPP was assessed by a standard 3 h IICr release assay as described by Ortaldo et al. (1977) . Control animals received an equal volume of PBS i.p. The results are shown in Figure 1 . A rapidly established and longlasting +4-fold increase in NK cell cytotoxicity is seen after the administration of either agent. (Talmadge et al., 1984) . (ii) Very high NK cell activity can be induced in the' lungs of rats by pyrimidinones (Lotzova et al., 1984) . (iii) Activated NK cells have been shown to produce a variety of lymphokines like IFN-gamma and IL-2 (Kasahara et al., 1983) .
IFN-gamma especially and a putative more rapidly working macrophage activating factor (MAF) secreted by NK cells in the rat and in man (Gomez et al., 1985) are very potent activators of alveolar macrophages.
The tumour site specific setting of a high concentration of (pyrimidinone-activated) macrophages further activated by NK-cell-secreted lymphokines could well explain the observed inhibition of the development of lung metastases. The difference in tumour reponse to ABPP and AIPP in the s.c. tumour model may be related to the difference in IFN serum levels after the administration of the two agents involved. When we observe the growth curve of the tumour in the ABPP pretreated group it is noted that the tumour seems to disappear over the first few days. This is the only antitumour effect observed since tumour growth follows a parallel course to the other experimental groups when the tumour becomes measurable.
Apparently tumour suppression is only short lived and no prolonged inhibitory effect can be observed. This could be explained by the fact that high IFN levels are induced by ABPP for a period of only 24h (Oku et al., 1984; Lotzova et al., 1984 (Oku et al., 1984) , as is observed with many biological response modifiers (Talmadge et al., 1985) , the antitumour effect in the s.c. model offers little prospect for an effective role for ABPP in this setting.
The anti-metastasis effect of these pyrimidinones is the more important observation, especially since the tumour used was NK resistant.
Interactions between activated NK cells and activated macrophages, both of which are present in high numbers in the lungs, may have overcome this resistance and may have brought about the effective lysis of the tumour cells by either cell population. Since the administration of pyrimidinones is virtually without toxicity or side effects (Earhart et al., 1985) these agents may hold some promise in boosting anti-metastasis protective mechanisms in a peri-operative or otherwise adjuvant setting.
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